Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TATE vs TACE in Intermediate Stage Hepatocellular Carcinoma
NCT03145558Phase 2Terminated
- Sponsor
- Teclison
- Start
- Dec 2017
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tirapazamine in hepatocellular carcinoma (HCC) (2 arms), sponsored by Teclison. Primary endpoint: Progression Free Survival at 2 years. Started Dec 2017; status: terminated.
02
Drugs
tirapazamine
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03145558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03145558.